OpenNashEarnings

ResMed (RMD) · Medical Devices

ResMed Q1 FY2027 earnings: summary, key numbers & outlook

Results filed 29 Oct 2026 · Quarter ended 30 Sep 2026

Slides (36 pages)Official transcript (PDF) ↗Press release ↗Investor relations ↗

Summaries and transcripts are machine-generated and can contain errors.

In brief

ResMed closed the MatrixCare divestiture and launched the AirTouch F40 fabric mask, refocusing on core sleep and breathing health and its connected digital ecosystem.

ResMed's quarter was driven by demand for sleep devices and masks in both the Americas and the rest of the world. It launched the AirTouch F40, its third fabric mask, plus the AirCurve 11 ST/ST-A bilevel device in the U.S. It also closed the MatrixCare sale and added partnerships with Eight Sleep and ŌURA to bring more people into sleep care.

Management is steering toward its core sleep and breathing business, a connected ecosystem and its 2030 strategy, backed by about $1.5 billion of planned buybacks and tuck-in M&A of up to about $500 million. The main tension is a second-half squeeze on rest-of-world device sales as the France fleet renewal concludes, plus a roughly 130 bps revenue headwind from Astral.

Slides & documents

Open the slide deck (PDF, 36 pages) ↗

ResMed Q1 FY2027 slide deck, page 1ResMed Q1 FY2027 slide deck, page 2ResMed Q1 FY2027 slide deck, page 3ResMed Q1 FY2027 slide deck, page 4ResMed Q1 FY2027 slide deck, page 5ResMed Q1 FY2027 slide deck, page 6

Showing the first 6 of 36 pages.

From ResMed investor relations

SEC filing

Key numbers

Revenue · GAAP
$1.4B

up 6% from a year ago

Net income · GAAP
$418.0M

up 20% from a year ago

Diluted EPS · GAAP
$2.92

up 23% from a year ago

Non-GAAP diluted EPS · non-GAAP
$2.91

up 14% from a year ago

Gross margin · GAAP
61.5%

up 30 bps from a year ago

Non-GAAP gross margin · non-GAAP
62.5%

up 50 bps from a year ago

Operating margin · GAAP
32.0%

down 140 bps from a year ago

Non-GAAP operating margin · non-GAAP
35.8%

down 30 bps from a year ago

Segment or metricValueChange
Americas Sleep Devices$436.0Mup 8% (6% core constant currency)
Americas Masks and other$397.0Mup 10%
Rest of World Sleep Devices$280.0Mup 12% (13% core constant currency)
Rest of World Masks and other$143.0Mup 12% (11% core constant currency)
Total Sleep and Breathing Health$1.3Bup 8% (7% core constant currency)
Residential Care Software$155.0Mdown 7% (up 5% core constant currency)
Where each number comes from
  • Revenue: “Financial Results and Operating Metrics (Unaudited; $ in millions, except for per share amounts) Three Months Ended September 30,2026 | September 30,2025 | % Change | ConstantCurrency (A) Revenue | $1,415 | $1,336 | 6% | 6%”
  • Net income: “Operating margin | 32.0% | 33.4% | (140) bps Non-GAAP income from operations (B) | 506 | 482 | 5 Non-GAAP operating margin (B) | 35.8% | 36.1% | (30) bps Net income | 418 | 349 | 20”
  • Diluted EPS: “Q1 GAAP diluted earnings per share up 23% to $2.92; non-GAAP diluted EPS up 14% to $2.91”
  • Non-GAAP diluted EPS: “Q1 GAAP diluted earnings per share up 23% to $2.92; non-GAAP diluted EPS up 14% to $2.91”
  • Gross margin: “Healthy profitability: GAAP gross margin of 61.5%. Non-GAAP gross margin increased 50 basis points to 62.5%, predominantly from productivity pipeline execution.”
  • Non-GAAP gross margin: “Non-GAAP gross margin increased 50 basis points to 62.5%, predominantly from productivity pipeline execution.”
  • Operating margin: “Robust earnings growth: GAAP operating margin of 32.0% and GAAP diluted earnings per share of $2.92. Non-GAAP operating margin of 35.8% and non-GAAP diluted earnings per share of $2.91”
  • Non-GAAP operating margin: “Non-GAAP operating margin of 35.8% and non-GAAP diluted earnings per share of $2.91, up 14% year-over-year, predominantly attributable to strong revenue growth and gross margin improvement.”
  • Americas Sleep Devices: “Americas Sleep Devices | $436 | $405 | 8% | 6% Masks and other | 397 | 361 | 10 | 10 Total Sleep | $833 | $766 | 9 | 8”
  • Americas Masks and other: “Americas Sleep Devices | $436 | $405 | 8% | 6% Masks and other | 397 | 361 | 10 | 10 Total Sleep | $833 | $766 | 9 | 8”
  • Rest of World Sleep Devices: “Rest of World Sleep Devices | $280 | $250 | 12% | 13% Masks and other | 143 | 128 | 12 | 11 Total Sleep | $423 | $378 | 12 | 12”
  • Rest of World Masks and other: “Rest of World Sleep Devices | $280 | $250 | 12% | 13% Masks and other | 143 | 128 | 12 | 11 Total Sleep | $423 | $378 | 12 | 12”
  • Total Sleep and Breathing Health: “Total Sleep and Breathing Health | $1,260 | $1,169 | 8 | 7 Residential Care Software | 155 | 166 | (7) | 5 Total | $1,415 | $1,336 | 6% | 7%”
  • Residential Care Software: “Total Sleep and Breathing Health | $1,260 | $1,169 | 8 | 7 Residential Care Software | 155 | 166 | (7) | 5 Total | $1,415 | $1,336 | 6% | 7%”

Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.

From the filingQ1 FY2027vs year agovs last quarter
Revenue$1.4B+5.9%−3.3%
Operating income$453.0M+1.4%+1.0%
Net income$418.4M+20.0%+9.1%
Diluted EPS$2.92+23.2%—
Free cash flow$373.7M−9.8%−7.4%
Gross margin61.5%+0.3 pts+2.7 pts
Operating margin32.0%−1.4 pts+1.3 pts

Calculated by code from XBRL, not by the model.

Outlook

MetricPeriodOutlook
Core constant currency revenue growthfiscal year 20275 - 7% growth
Reported revenuefiscal year 2027$5.75 - $5.85 Billion
Non-GAAP diluted EPSfiscal year 2027$12.00 - $12.25

Key takeaways

  1. AirTouch F40 extends ResMed's fabric mask line

    ResMed launched the AirTouch F40 in the U.S. as its third fabric mask. Its ComfiSoft cushion adapts through the night, and 91% rated it comfortable at initial fitting.

  2. Personalized myAir features aim to lift compliance

    Resmed's AI-powered myAir, with the Dawn GenAI coach, reached 2.1M+ inquiries, up 40%. It reports a 4.3% increase in 30-day compliance versus default settings.

  3. MatrixCare exit sharpens focus on core sleep

    The MatrixCare sale closed September 1, 2026. Management says it improves the growth, mix and focus of Residential Care Software, whose remaining Brightree and MEDIFOX DAN businesses grew 8%.

  4. GLP-1 data counters fears of lower CPAP demand

    An IQVIA analysis of 3,307,000 patients found GLP-1 users were 1170 bps more likely to initiate PAP therapy. Resupply rates were also higher, by 350 bps at 1 year and 730 bps at 3 years.

  5. Partnerships and Nidra widen the patient funnel

    Eight Sleep and ŌURA partnerships connect sleep insights to ResMed's assessment and care pathways. ResMed also closed the Nidra restless legs syndrome acquisition on June 1, 2026, and is prioritizing commercial coverage.

Charts

Revenue$1.4B+5.9% y/yQ1 FY27
Q2 FY25: $1.3BQ2 25$1.3BQ3 FY25: $1.3BQ3 25$1.3BQ4 FY25: $1.3B (worked out from the annual figure)Q4 25$1.3BQ1 FY26: $1.3BQ1 26$1.3BQ2 FY26: $1.4BQ2 26$1.4BQ3 FY26: $1.4BQ3 26$1.4BQ4 FY26: $1.5B (worked out from the annual figure)Q4 26$1.5BQ1 FY27: $1.4BQ1 27$1.4B

Fourth quarter worked out from the annual figure.

Data
Q2 FY25$1.3B
Q3 FY25$1.3B
Q4 FY25$1.3B *
Q1 FY26$1.3B
Q2 FY26$1.4B
Q3 FY26$1.4B
Q4 FY26$1.5B *
Q1 FY27$1.4B
Diluted EPS (GAAP)$2.92+23.2% y/yQ1 FY27
Q2 FY25: $2.34Q2 25$2.34Q3 FY25: $2.48Q3 25$2.48Q1 FY26: $2.37Q1 26$2.37Q2 FY26: $2.68Q2 26$2.68Q3 FY26: $2.74Q3 26$2.74Q1 FY27: $2.92Q1 27$2.92
Data
Q2 FY25$2.34
Q3 FY25$2.48
Q1 FY26$2.37
Q2 FY26$2.68
Q3 FY26$2.74
Q1 FY27$2.92

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin32.0%−1.4 pts y/yQ1 FY27
Q2 FY25: 32.5%Q2 2532.5%Q3 FY25: 33.0%Q3 2533.0%Q4 FY25: 33.7%Q4 2533.7%Q1 FY26: 33.4%Q1 2633.4%Q2 FY26: 34.6%Q2 2634.6%Q3 FY26: 34.9%Q3 2634.9%Q4 FY26: 30.7%Q4 2630.7%Q1 FY27: 32.0%Q1 2732.0%
Data
Q2 FY2532.5%
Q3 FY2533.0%
Q4 FY2533.7%
Q1 FY2633.4%
Q2 FY2634.6%
Q3 FY2634.9%
Q4 FY2630.7%
Q1 FY2732.0%
Free cash flow$373.7M−9.8% y/yQ1 FY27
Q2 FY25: $288.0MQ2 25$288.0MQ3 FY25: $557.9MQ3 25$557.9MQ4 FY25: $508.2MQ4 25$508.2MQ1 FY26: $414.4MQ1 26$414.4MQ2 FY26: $311.2MQ2 26$311.2MQ3 FY26: $520.5MQ3 26$520.5MQ4 FY26: $403.5MQ4 26$403.5MQ1 FY27: $373.7MQ1 27$373.7M
Data
Q2 FY25$288.0M
Q3 FY25$557.9M
Q4 FY25$508.2M
Q1 FY26$414.4M
Q2 FY26$311.2M
Q3 FY26$520.5M
Q4 FY26$403.5M
Q1 FY27$373.7M

Operating cash flow minus capital expenditure, from cash flow statements.

Questions

What new products did ResMed launch this quarter?

ResMed launched the AirTouch F40, its third fabric CPAP mask, in the U.S. It also introduced the AirCurve 11 ST/ST-A bilevel device and expanded myAir personalization features.

How is ResMed responding to GLP-1 weight-loss drugs?

It points to an IQVIA analysis of 3,307,000 patients showing GLP-1 users were 1170 bps more likely to initiate PAP therapy and had higher resupply rates.

Why did ResMed sell MatrixCare?

Management says the sale accelerates growth and profitability of core Residential Care Software, improves mix and sharpens execution focus. It closed on September 1, 2026.

What is ResMed doing to reach more undiagnosed sleep apnea patients?

It is partnering with Eight Sleep and ŌURA and running marketing campaigns, including one with NASCAR driver Tyler Reddick. In the ŌURA pathway, about 72% of assessment takers were undiagnosed.

What risks does ResMed flag for the rest of fiscal 2027?

It flags second-half pressure on rest-of-world sleep devices as the France fleet renewal concludes, a roughly 130 bps revenue headwind from Astral, and a larger FX headwind of about 60 bps.

Call recording

Call recording on YouTube ↗. Official replay ↗.

Read ResMed's official transcript ↗.